🚀 VC round data is live in beta, check it out!
Delcath Systems Valuation Multiples
Discover revenue and EBITDA valuation multiples for Delcath Systems and similar public comparables like VieMed, TaiDoc Technology, Medios, Standard BioTools and more.
Delcath Systems Overview
About Delcath Systems
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Founded
1988
HQ
Employees
96
Website
Financials (LTM)
EV
$285M
Delcath Systems Financials
Delcath Systems reported last 12-month revenue of $91M and EBITDA of $16M.
In the same LTM period, Delcath Systems generated $78M in gross profit, $16M in EBITDA, and had net loss of ($5M).
Revenue (LTM)
Delcath Systems P&L
In the most recent fiscal year, Delcath Systems reported revenue of $85M and EBITDA of $25M.
Delcath Systems expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $91M | XXX | $85M | XXX | XXX | XXX |
| Gross Profit | $78M | XXX | $73M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | $16M | XXX | $25M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | (8%) | XXX | 1% | XXX | XXX | XXX |
| Net Profit | ($5M) | XXX | $3M | XXX | XXX | XXX |
| Net Margin | (6%) | XXX | 3% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Delcath Systems Stock Performance
Delcath Systems has current market cap of $375M, and enterprise value of $285M.
Market Cap Evolution
Delcath Systems' stock price is $10.88.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $285M | $375M | 0.0% | XXX | XXX | XXX | $0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDelcath Systems Valuation Multiples
Delcath Systems trades at 3.1x EV/Revenue multiple, and 17.9x EV/EBITDA.
EV / Revenue (LTM)
Delcath Systems Financial Valuation Multiples
As of April 19, 2026, Delcath Systems has market cap of $375M and EV of $285M.
Equity research analysts estimate Delcath Systems' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Delcath Systems has a P/E ratio of (70.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $375M | XXX | $375M | XXX | XXX | XXX |
| EV (current) | $285M | XXX | $285M | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 17.9x | XXX | 11.3x | XXX | XXX | XXX |
| EV/EBIT | (40.3x) | XXX | 417.0x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | 3.9x | XXX | XXX | XXX |
| P/E | (70.1x) | XXX | 138.8x | XXX | XXX | XXX |
| EV/FCF | 19.9x | XXX | 12.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Delcath Systems Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Delcath Systems Margins & Growth Rates
Delcath Systems' revenue in the last 12 month grew by 26%.
Delcath Systems' revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.8M for the same period.
Delcath Systems' rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Delcath Systems' rule of X is 49% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Delcath Systems Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 26% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | (111%) | XXX | (123%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 49% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 55% | XXX | 51% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 40% | XXX | 34% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 85% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Delcath Systems Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Delcath Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| VieMed | XXX | XXX | XXX | XXX | XXX | XXX |
| TaiDoc Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| Medios | XXX | XXX | XXX | XXX | XXX | XXX |
| Standard BioTools | XXX | XXX | XXX | XXX | XXX | XXX |
| Universal Vision | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Delcath Systems M&A Activity
Delcath Systems acquired XXX companies to date.
Last acquisition by Delcath Systems was on XXXXXXXX, XXXXX. Delcath Systems acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Delcath Systems
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDelcath Systems Investment Activity
Delcath Systems invested in XXX companies to date.
Delcath Systems made its latest investment on XXXXXXXX, XXXXX. Delcath Systems invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Delcath Systems
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Delcath Systems
| When was Delcath Systems founded? | Delcath Systems was founded in 1988. |
| Where is Delcath Systems headquartered? | Delcath Systems is headquartered in United States. |
| How many employees does Delcath Systems have? | As of today, Delcath Systems has over 96 employees. |
| Who is the CEO of Delcath Systems? | Delcath Systems' CEO is Gerard J. Michel. |
| Is Delcath Systems publicly listed? | Yes, Delcath Systems is a public company listed on Nasdaq. |
| What is the stock symbol of Delcath Systems? | Delcath Systems trades under DCTH ticker. |
| When did Delcath Systems go public? | Delcath Systems went public in 2000. |
| Who are competitors of Delcath Systems? | Delcath Systems main competitors are VieMed, TaiDoc Technology, Medios, Standard BioTools. |
| What is the current market cap of Delcath Systems? | Delcath Systems' current market cap is $375M. |
| What is the current revenue of Delcath Systems? | Delcath Systems' last 12 months revenue is $91M. |
| What is the current revenue growth of Delcath Systems? | Delcath Systems revenue growth (NTM/LTM) is 26%. |
| What is the current EV/Revenue multiple of Delcath Systems? | Current revenue multiple of Delcath Systems is 3.1x. |
| Is Delcath Systems profitable? | Yes, Delcath Systems is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Delcath Systems? | Delcath Systems' last 12 months EBITDA is $16M. |
| What is Delcath Systems' EBITDA margin? | Delcath Systems' last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Delcath Systems? | Current EBITDA multiple of Delcath Systems is 17.9x. |
| What is the current FCF of Delcath Systems? | Delcath Systems' last 12 months FCF is $14M. |
| What is Delcath Systems' FCF margin? | Delcath Systems' last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Delcath Systems? | Current FCF multiple of Delcath Systems is 19.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.